A national case-control study investigating demographic and environmental factors associated with NMOSD.
NMOSD
aquaporin-4
epidemiology
risk factors
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
medline:
1
5
2023
pubmed:
22
2
2023
entrez:
21
2
2023
Statut:
ppublish
Résumé
Risk factors for aquaporin-4 (AQP4+) antibody neuromyelitis optica spectrum disorder (NMOSD) are not well-established. To investigate demographic and environmental factors associated with NMOSD using a validated questionnaire and case-control design. We enrolled patients with AQP4 + NMOSD through six Canadian Multiple Sclerosis Clinics. Participants completed the validated Environmental Risk Factors in Multiple Sclerosis Study (EnvIMS) questionnaire. Their responses were compared to those of 956 unaffected controls from the Canadian arm of EnvIMS. We calculated odds ratios (ORs) for the association between each variable and NMOSD using logistic regression and Firth's procedure for rare events. In 122 participants (87.7% female) with NMOSD, odds of NMOSD in East Asian and Black participants were ⩾8 times that observed in White participants. Birthplace outside Canada was associated with an increased risk of NMOSD (OR = 5.5, 95% confidence interval (CI) = 3.6-8.3) as were concomitant autoimmune diseases (OR = 2.7, 95% CI = 1.4-5.0). No association was observed with reproductive history or age at menarche. In this case-control study, risk of NMOSD in East Asian and Black versus White individuals was greater than that observed in many previous studies. Despite the preponderance of affected women, we did not observe any association with hormonal factors such as reproductive history or age at menarche.
Sections du résumé
BACKGROUND
Risk factors for aquaporin-4 (AQP4+) antibody neuromyelitis optica spectrum disorder (NMOSD) are not well-established.
OBJECTIVE
To investigate demographic and environmental factors associated with NMOSD using a validated questionnaire and case-control design.
METHODS
We enrolled patients with AQP4 + NMOSD through six Canadian Multiple Sclerosis Clinics. Participants completed the validated Environmental Risk Factors in Multiple Sclerosis Study (EnvIMS) questionnaire. Their responses were compared to those of 956 unaffected controls from the Canadian arm of EnvIMS. We calculated odds ratios (ORs) for the association between each variable and NMOSD using logistic regression and Firth's procedure for rare events.
RESULTS
In 122 participants (87.7% female) with NMOSD, odds of NMOSD in East Asian and Black participants were ⩾8 times that observed in White participants. Birthplace outside Canada was associated with an increased risk of NMOSD (OR = 5.5, 95% confidence interval (CI) = 3.6-8.3) as were concomitant autoimmune diseases (OR = 2.7, 95% CI = 1.4-5.0). No association was observed with reproductive history or age at menarche.
CONCLUSION
In this case-control study, risk of NMOSD in East Asian and Black versus White individuals was greater than that observed in many previous studies. Despite the preponderance of affected women, we did not observe any association with hormonal factors such as reproductive history or age at menarche.
Identifiants
pubmed: 36803237
doi: 10.1177/13524585231151953
pmc: PMC10152218
doi:
Substances chimiques
Aquaporin 4
0
Autoantibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
521-529Références
Medicine (Baltimore). 2021 Sep 17;100(37):e27234
pubmed: 34664866
Mult Scler Relat Disord. 2019 Jan;27:350-363
pubmed: 30476871
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Mult Scler. 2015 May;21(6):703-9
pubmed: 25305254
Ann Neurol. 2016 May;79(5):775-783
pubmed: 26891082
Sci Rep. 2020 Aug 13;10(1):13706
pubmed: 32792643
N Engl J Med. 2021 Oct 7;385(15):1429-1430
pubmed: 34516052
Front Neurol. 2020 Jun 26;11:501
pubmed: 32670177
Neurol Neuroimmunol Neuroinflamm. 2017 Mar 24;4(3):e339
pubmed: 28382320
Neurology. 2014 Nov 18;83(21):1923-9
pubmed: 25339213
Acta Neurol Belg. 2018 Jun;118(2):277-287
pubmed: 29500680
PLoS One. 2013;8(2):e57646
pubmed: 23469038
Curr Opin Rheumatol. 2019 Jan;31(1):53-61
pubmed: 30394940
Neurology. 2019 Dec 10;93(24):e2203-e2215
pubmed: 31690681
BMC Med Res Methodol. 2019 Jul 1;19(1):135
pubmed: 31262266
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):632-638
pubmed: 28550069
Neuroepidemiology. 2015;44(3):173-81
pubmed: 25967369
Brain. 2012 Jun;135(Pt 6):1834-49
pubmed: 22577216
Mult Scler Relat Disord. 2021 Sep;54:103110
pubmed: 34214879
Stat Med. 2017 Jun 30;36(14):2302-2317
pubmed: 28295456
Mult Scler. 2012 Jan;18(1):5-10
pubmed: 22146604
Ann Clin Transl Neurol. 2020 Nov;7(11):2082-2093
pubmed: 32979043
Nat Rev Neurol. 2020 Mar;16(3):154-170
pubmed: 32080393
Neurology. 2018 Nov 27;91(22):e2089-e2099
pubmed: 30366977
Neurology. 2019 Jul 9;93(2):e181-e189
pubmed: 31171648
Neurology. 2021 Jan 12;96(2):59-77
pubmed: 33310876
N Engl J Med. 2017 Aug 3;377(5):465-475
pubmed: 28767357
Neurology. 2018 Dec 11;91(24):e2265-e2275
pubmed: 30413632
J Neuroimmunol. 2021 Jul 15;356:577581
pubmed: 33940232
Acta Neurol Scand Suppl. 2012;(195):43-50
pubmed: 23278656
Rev Neurol (Paris). 2009 Aug-Sep;165(8-9):676-83
pubmed: 19406445
J Neuroimmunol. 2016 Apr 15;293:65-70
pubmed: 27049564